These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries. Gozalbes R; Simon L; Froloff N; Sartori E; Monteils C; Baudelle R J Med Chem; 2008 Jun; 51(11):3124-32. PubMed ID: 18479119 [TBL] [Abstract][Full Text] [Related]
5. A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors. Schulz MN; Fanghänel J; Schäfer M; Badock V; Briem H; Boemer U; Nguyen D; Husemann M; Hillig RC Acta Crystallogr D Biol Crystallogr; 2011 Mar; 67(Pt 3):156-66. PubMed ID: 21358046 [TBL] [Abstract][Full Text] [Related]
6. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. Graczyk PP J Med Chem; 2007 Nov; 50(23):5773-9. PubMed ID: 17948979 [TBL] [Abstract][Full Text] [Related]
7. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome. Martin E; Mukherjee P J Chem Inf Model; 2012 Jan; 52(1):156-70. PubMed ID: 22133092 [TBL] [Abstract][Full Text] [Related]
8. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. Bamborough P; Drewry D; Harper G; Smith GK; Schneider K J Med Chem; 2008 Dec; 51(24):7898-914. PubMed ID: 19035792 [TBL] [Abstract][Full Text] [Related]
9. Identification of pyrrolo[2,3-g]indazoles as new Pim kinase inhibitors. Gavara L; Suchaud V; Nauton L; Théry V; Anizon F; Moreau P Bioorg Med Chem Lett; 2013 Apr; 23(8):2298-301. PubMed ID: 23499503 [TBL] [Abstract][Full Text] [Related]
10. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746 [TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases. Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169 [TBL] [Abstract][Full Text] [Related]
12. The design, annotation, and application of a kinase-targeted library. Xi H; Lunney EA Methods Mol Biol; 2011; 685():279-91. PubMed ID: 20981529 [TBL] [Abstract][Full Text] [Related]
13. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors. Bogusz J; Zrubek K; Rembacz KP; Grudnik P; Golik P; Romanowska M; Wladyka B; Dubin G Sci Rep; 2017 Oct; 7(1):13399. PubMed ID: 29042609 [TBL] [Abstract][Full Text] [Related]
14. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148 [TBL] [Abstract][Full Text] [Related]
15. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. Lyne PD; Lamb ML; Saeh JC J Med Chem; 2006 Aug; 49(16):4805-8. PubMed ID: 16884290 [TBL] [Abstract][Full Text] [Related]